• Exchange: Berlin
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

ThromboGenics NV

+ Add to Watchlist

TG4:GR

8.520 EUR 0.422 4.72%

As of 06:59:24 ET on 07/11/2014.

Snapshot for ThromboGenics NV (TG4)

Open: 8.583 Day's Range: 8.500 - 8.687 Volume: 325
Previous Close: 8.942 52wk Range: 8.500 - 33.200 1-Yr Rtn: -73.07%

Stock Chart for TG4

No chart data available.
  • TG4:GR 8.520
  • 1D
  • 1M
  • 1Y
8.942
Interactive TG4 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for TG4

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (EUR) (ttm) -
Est. EPS (EUR) (12/2014) -1.3930
Est. PEG Ratio -
Market Cap (M EUR) 307.52
Shares Outstanding (M) 36.09
30 Day Average Volume 517
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/28/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for TG4

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for TG4

ThromboGenics NV is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company is focused on developing medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system.

Gustaaf Van Reet "Staf"ChairmanPatrik De HaesCEO/Executive Director
Luc PhilipsInterim CFOKoen KasChief Scientific Officer
More Company Profile & Key Executives for TG4

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil